View in EDS HTML Full Text PDF Full Text

Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants.

Saved in:
Bibliographic Details
Title: Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants.
Authors: Li, Xue‐Qing1 (AUTHOR), Lindmark, Bo1 (AUTHOR), Amilon, Carl1 (AUTHOR), Samuelsson, Kristin1 (AUTHOR), Weidolf, Lars1 (AUTHOR), Nelander, Karin2 (AUTHOR), Knöchel, Jane3 (AUTHOR), Heijer, Maria4 (AUTHOR), Bragg, Ryan A.5 (AUTHOR), Gränfors, Malin6 (AUTHOR), Lindstedt, Eva‐Lotte7 (AUTHOR), Sidhu, Sharan8 (AUTHOR), Garkaviy, Pavlo9 (AUTHOR), Ericsson, Hans3 (AUTHOR) hans.ericsson@astrazeneca.com
Source: Pharmacology Research & Perspectives. Oct2024, Vol. 12 Issue 5, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20521707
DOI:10.1002/prp2.70029